Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience

Katsuyuki Hotta; Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Atsuko Ogino; Shigeki Umemura; Shingo Harita; Kenichi Gemba; Toshiro Yonei; Akihiro Bessho; Tadashi Maeda; Mitsune Tanimoto

doi:10.1080/02841860500256215

Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience

Katsuyuki Hotta, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Atsuko Ogino, Shigeki Umemura, Shingo Harita, Kenichi Gemba, Toshiro Yonei, Akihiro Bessho, Tadashi Maeda, Mitsune Tanimoto

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

We evaluated the safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer (NSCLC). We retrospectively compared toxicity, response and survival outcomes for gefitinib in patients aged 75 years or older (elderly group) with the same outcomes in patients aged younger than 75 years. In total, 350 patients were eligible for this analysis, of whom 92 were in the elderly group and 258 in the non-elderly group. In the elderly group, adverse events were generally mild to moderate and grade 3-4 adverse events were observed in 8 (9%) patients. The objective response rate (17 vs. 21% for elderly vs. non-elderly, respectively) and median survival time (7.6 vs. 9.3 months) were also similar in the two groups. Multivariate analysis revealed elderly patients with lower Brinkman index tended to be more sensitive to gefitinib (odds ratio: 4.57, 95% confidence interval: 0.91-22.72, p = 0.0642). In this study, treatment with gefitinib appeared to be as safe and effective in elderly patients (aged 75 or older) with NSCLC as in non-elderly patients.

Original language	English
Pages (from-to)	717-722
Number of pages	6
Journal	Acta Oncologica
Volume	44
Issue number	7
DOIs	https://doi.org/10.1080/02841860500256215
Publication status	Published - 2005

ASJC Scopus subject areas

Hematology
Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1080/02841860500256215

Fingerprint Dive into the research topics of 'Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience'. Together they form a unique fingerprint.

Cite this

Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer : Okayama Lung Cancer Study Group experience. / Hotta, Katsuyuki; Ueoka, Hiroshi; Kiura, Katsuyuki ; Tabata, Masahiro; Ogino, Atsuko; Umemura, Shigeki; Harita, Shingo; Gemba, Kenichi; Yonei, Toshiro; Bessho, Akihiro; Maeda, Tadashi; Tanimoto, Mitsune.

In: Acta Oncologica, Vol. 44, No. 7, 2005, p. 717-722.

Research output: Contribution to journal › Article › peer-review

Hotta, Katsuyuki ; Ueoka, Hiroshi ; Kiura, Katsuyuki ; Tabata, Masahiro ; Ogino, Atsuko ; Umemura, Shigeki ; Harita, Shingo ; Gemba, Kenichi ; Yonei, Toshiro ; Bessho, Akihiro ; Maeda, Tadashi ; Tanimoto, Mitsune. / Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer : Okayama Lung Cancer Study Group experience. In: Acta Oncologica. 2005 ; Vol. 44, No. 7. pp. 717-722.

@article{4c520a7816ae46d29750040d5e1f9d52,

title = "Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience",

abstract = "We evaluated the safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer (NSCLC). We retrospectively compared toxicity, response and survival outcomes for gefitinib in patients aged 75 years or older (elderly group) with the same outcomes in patients aged younger than 75 years. In total, 350 patients were eligible for this analysis, of whom 92 were in the elderly group and 258 in the non-elderly group. In the elderly group, adverse events were generally mild to moderate and grade 3-4 adverse events were observed in 8 (9%) patients. The objective response rate (17 vs. 21% for elderly vs. non-elderly, respectively) and median survival time (7.6 vs. 9.3 months) were also similar in the two groups. Multivariate analysis revealed elderly patients with lower Brinkman index tended to be more sensitive to gefitinib (odds ratio: 4.57, 95% confidence interval: 0.91-22.72, p = 0.0642). In this study, treatment with gefitinib appeared to be as safe and effective in elderly patients (aged 75 or older) with NSCLC as in non-elderly patients.",

author = "Katsuyuki Hotta and Hiroshi Ueoka and Katsuyuki Kiura and Masahiro Tabata and Atsuko Ogino and Shigeki Umemura and Shingo Harita and Kenichi Gemba and Toshiro Yonei and Akihiro Bessho and Tadashi Maeda and Mitsune Tanimoto",

year = "2005",

doi = "10.1080/02841860500256215",

language = "English",

volume = "44",

pages = "717--722",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Informa Healthcare",

number = "7",

}

TY - JOUR

T1 - Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer

T2 - Okayama Lung Cancer Study Group experience

AU - Hotta, Katsuyuki

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Ogino, Atsuko

AU - Umemura, Shigeki

AU - Harita, Shingo

AU - Gemba, Kenichi

AU - Yonei, Toshiro

AU - Bessho, Akihiro

AU - Maeda, Tadashi

AU - Tanimoto, Mitsune

PY - 2005

Y1 - 2005

N2 - We evaluated the safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer (NSCLC). We retrospectively compared toxicity, response and survival outcomes for gefitinib in patients aged 75 years or older (elderly group) with the same outcomes in patients aged younger than 75 years. In total, 350 patients were eligible for this analysis, of whom 92 were in the elderly group and 258 in the non-elderly group. In the elderly group, adverse events were generally mild to moderate and grade 3-4 adverse events were observed in 8 (9%) patients. The objective response rate (17 vs. 21% for elderly vs. non-elderly, respectively) and median survival time (7.6 vs. 9.3 months) were also similar in the two groups. Multivariate analysis revealed elderly patients with lower Brinkman index tended to be more sensitive to gefitinib (odds ratio: 4.57, 95% confidence interval: 0.91-22.72, p = 0.0642). In this study, treatment with gefitinib appeared to be as safe and effective in elderly patients (aged 75 or older) with NSCLC as in non-elderly patients.

AB - We evaluated the safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer (NSCLC). We retrospectively compared toxicity, response and survival outcomes for gefitinib in patients aged 75 years or older (elderly group) with the same outcomes in patients aged younger than 75 years. In total, 350 patients were eligible for this analysis, of whom 92 were in the elderly group and 258 in the non-elderly group. In the elderly group, adverse events were generally mild to moderate and grade 3-4 adverse events were observed in 8 (9%) patients. The objective response rate (17 vs. 21% for elderly vs. non-elderly, respectively) and median survival time (7.6 vs. 9.3 months) were also similar in the two groups. Multivariate analysis revealed elderly patients with lower Brinkman index tended to be more sensitive to gefitinib (odds ratio: 4.57, 95% confidence interval: 0.91-22.72, p = 0.0642). In this study, treatment with gefitinib appeared to be as safe and effective in elderly patients (aged 75 or older) with NSCLC as in non-elderly patients.

UR - http://www.scopus.com/inward/record.url?scp=27544436958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544436958&partnerID=8YFLogxK

U2 - 10.1080/02841860500256215

DO - 10.1080/02841860500256215

M3 - Article

C2 - 16227162

AN - SCOPUS:27544436958

VL - 44

SP - 717

EP - 722

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 7

ER -